## Everolimus improves the efficacy of dasatinib in the treatment of

## PDGFRA-driven glioma

Zachary Miklja<sup>1^</sup>, Viveka Nand Yadav<sup>1^</sup>, Rodrigo Cartaxo<sup>1</sup>, Ruby Siada<sup>1</sup>, Brendan Mullan<sup>1</sup>, Stefanie Stallard<sup>1</sup>, Alyssa Paul<sup>1</sup>, Amy K. Bruzek<sup>2</sup>, Kyle Wierzbicki<sup>1</sup>, Tao Yang<sup>4</sup>, Taylor Garcia<sup>1</sup>, Ian Wolfe<sup>1</sup>, Hemant Parmar<sup>6</sup>, Marcia Leonard<sup>1</sup>, Patricia L. Robertson<sup>1</sup>, Hugh Garton<sup>2</sup>, Sriram Venneti<sup>3</sup>, Chandan Kumar-Sinha<sup>3,5</sup>, Arul Chinnaiyan<sup>3,5,8,9</sup>, Rajen Mody<sup>1</sup>, Manjunath P. Pai<sup>11</sup>, Timothy N. Phoenix<sup>12</sup>, Bernard L. Marini<sup>11</sup>, Carl Koschmann<sup>1\*</sup>

\*Correspondence to: <a href="mailto:ckoschma@med.umich.edu">ckoschma@med.umich.edu</a>

## This PDF file includes:

Supplementary methods Supplementary figure legends

"\*corresponding author"

"^denotes equal contribution"

## **Supplemental materials**

#### Supplementary methods

### P-gp assay

*In vitro* P-gp inhibitor assay was performed with the Pgp-Glo<sup>™</sup> Assay System (Promega). Assay methods were executed as described in the supplied protocol. Briefly, the assay detected the effects of compounds on recombinant human P-gp in a cell membrane fraction. The assay utilized the ATP dependence of the light-generating reaction (firefly luciferase) of ATPase inhibition. Verapamil is a P-gp substrate that stimulates P-gp ATPase activity and, within the assay, functions as a P-gp stimulator (negative control). Sodium orthovanadate (Na<sub>3</sub>VO<sub>4</sub>) provides a measure of P-gp independent ATPase activity and was used as a P-gp inhibitor (positive control) within this assay. All experimental conditions were briefly rocked on a plate shaker and then put in an incubator at 37°C and 5% CO<sub>2</sub> for 3.5 hours. After this incubation period, all conditions were again briefly rocked on a plate shaker and incubated at room temperature for 20 minutes to allow luminescent signal to develop. Luminescent signal (ATM inhibition) was read on a Synergy HTX Multi-Mode microplate reader (BioTek).

Tumor DNA analysis was performed by droplet digital PCR (ddPCR), a highly sensitive PCR method that can detect low copy numbers of DNA, including ctDNA, in CSF. PCR primers and fluorescent probes were designed for the wild-type PDGFRA and mutant D842V sequences, as well as the target amplification region. An additional assay was designed for the housekeeping gene AP3B1 to be used as a reference (Bio-Rad). Patient sample CSF underwent ddPCR to document baseline CSF tDNA in UMPED52 and baseline CSF tDNA PDGFRA copy number in UMPED44. The Bio-Rad QX200 AutoDG system was used for all ddPCR work, and Bio-Rad QuantaSoft Analysis Pro was used for analysis of results.

#### Western blot and immunohistochemistry

PDGFRA pathway expression was assessed in primary HGG cell cultures and mouse brain/ tumor tissue via immunocytochemistry (1:500) and western blotting (1:1000) with PDGF Receptor α antibody (Cell Signaling, sc-3174S) and Phospho-PDGF Receptor α antibody (Cell Signaling sc-3170S). Phospho-AKT expression in PDGFRA-driven HGG mouse brain and tumor tissue was assessed by immunohistochemistry with Phospho-AKT antibody (Cell Signaling, #9271S). Pglycoprotein (P-gp) expression in PDGFRA-driven HGG mouse brain and tumor tissue was assessed by immunohistochemistry (1:50) with P-gp antibody (Santa Cruz Biotechnology, sc-390883). Supplementary Figures







Figure S1: Characterization of IUE PPK generated tumors and primary cell culture A) IHC for IUE PPK generated tumors depicting high-grade features including necrosis and vascular proliferation (top right box). Tumors demonstrated staining for H3K27M, negative staining for H3K27me3, and increased total PDGFRA. B) PDGFRA western quantification for total PDGFRA and p-PDGFRA normalized to vinculin signal for PPK cells treated with various dasatinib doses in vitro. Scale bars: A(top): left 200 µm, right 100 µm; (bottom) up 200 µm, down 50 µm



**Figure S2:** Sensitivity of human primary cell cultures to treatment with dasatinib **A)** Dasatinib dose-response curve for various cancer types (data from the Sanger Institute – Genomics of Drug Sensitivity). Most low grade glioma and glioblastoma mutiforme cell cultures were sensitive to dasatinib within 0.01 to 1  $\mu$ M ranges (red region). **B)** UMPED58 (*PDGFRA*-amplified DIPG cell culture) dose response curve with dasatinib monotherapy. **C)** UMPED58 growth response after addition of PDGF ligand  $\alpha$  and  $\beta$  (\*\*\*\* *P* ≤ 0.00005 by Welch's t-test).

# B UMPED58 Dasatinib Monotherapy


10

uМ


1

 $IC_{50} = 50 \text{ nM}$ 


100 10001000000000




**Figure S3:** Dasatinib and everolimus efficacy in PPK neurospheres and P-gp inhibition over time. **A)** Pixel area of the largest PPK neurosphere by fluorescent microscopy for different treatment conditions (\*\*\*  $P \le 0.0005$ , \*\*\*\*  $P \le 0.0005$  by Welch's t-test). **B)** P-gp inhibition over time using *in vitro* assay.




**Figure S4:** Pharmacokinetic (PK) analysis of dasatinib concentrations in non-tumor mouse model **A**) Schematic of PK mouse studies (tail vein injection (TVI) and oral gavage (OG)). **B**) Dasatinib plasma concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **C**) Dasatinib cortex concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **D**) Dasatinib brainstem concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **D**) Dasatinib brainstem concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **E**) Dasatinib concentration (ng/mL) for plasma, cortex, and brainstem over time when treated with dasatinib alone. **F**) Dasatinib concentration (ng/mL) for plasma, cortex, and brainstem over time when treated with dasatinib and everolimus.



**Figure S5:** PK analysis of everolimus blood and brain concentration in non-tumor mouse model **A**) Everolimus plasma concentrations of (ng/mL) over time after treatment with everolimus. **B**) Everolimus brain concentrations (ng/g) over time after treatment with everolimus.




B pAKT Expression



С

PDFGR Expression



**Figure S6:** Immunohistochemistry of mouse tumors treated immediately prior to processing. **A)** P-gp expression in the treated condition was shown to be reduced when compared to the untreated condition (\*\*\*  $P \le 0.0005$  by Welch's t-test). Red arrows represent positive staining cells. **B)** pAKT expression in the treated condition was shown to be reduced when compared to the untreated condition (\*  $P \le 0.05$  by Welch's t-test). **C)** PDFGFR expression in the treated condition was shown to be reduced when compared when compared to the untreated condition (\*\*  $P \le 0.05$  by Welch's t-test). **C)** PDFGFR expression in the treated condition was shown to be reduced when compared to the untreated condition (\*\*  $P \le 0.005$  by Welch's t-test). **C)** PDFGFR expression in the treated condition was shown to be reduced when compared to the untreated condition (\*\*  $P \le 0.005$  by Welch's t-test). **C)** PDFGFR expression in the treated condition was shown to be reduced when compared to the untreated condition (\*\*  $P \le 0.005$  by Welch's t-test). **C)** PDFGFR expression in the treated condition was shown to be reduced when compared to the untreated condition (\*\*  $P \le 0.005$  by Welch's t-test). Scale bars (from left to right): 200 µm; 200 µm; 50 µm.





Figure S7: Pharmacokinetic analysis of dasatinib concentrations in plasma and CSF in patients A) Comparison of plasma dasatinib concentrations for dasatinib alone and dasatinib and everolimus co-treatment for UMPED44 and UMPED52. B) Comparison of CSF dasatinib concentrations for dasatinib alone and dasatinib and everolimus co-treatment conditions for UMPED44.




## B UMPED52 Somatic Variants

Gene	Effect	Protein Change	Variant Allele Fraction
PDGFRA	Missense	p.D842V	28%
DCC	Missense	p.T146I	31%
ACVR2B	Missense	p.E1039*	20%


#### UMPED52 baseline CSF tDNA

С





**Figure S8:** Molecular attributes and tumor imaging of *PDGFRA*-mutated tail patient (UMPED52) **A)** UMPED52 copy number profile with estimated tumor content. **B)** UMPED52 somatic variants with a *PDGFRA* variant allele fraction of 34%. **C)** UMPED52 baseline CSF tDNA documenting PDGFRA D824V allele fraction. **D)** Serial UMPED52 MRI (axial FLAIR T2) during therapy.



**Figure S9:** PedcBioPortal (adult HGG) P-gp RNA-seq data **A)** No statistical significance was found between P-gp expression and *PDFGRA* status, age at diagnosis, or *MGMT* status within these adult data sets.